Article

Two bottle limit defines optimal medical therapy

San Francisco - Optimal medical therapy for most patients needing IOP-lowering treatment may be as simple as one or two bottles, said Robert D. Fechtner, MD, professor of ophthalmology, director, glaucoma division, Institute of Ophthalmology and Visual Science, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark.

San Francisco - Optimal medical therapy for most patients needing IOP-lowering treatment may be as simple as one or two bottles, said Robert D. Fechtner, MD, professor of ophthalmology, director, glaucoma division, Institute of Ophthalmology and Visual Science, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark.

“Addition of a third bottle rarely provides substantial additional reduction in IOP, so I would recommend changing the second drug before going to a third, and if that fails, consider laser or incisional surgery next,” he commented.

Ophthalmologists who prescribe medications for glaucoma need to realize that it is the patient who is really treating the disease, not the physician, and so the reality is that there may be no relationship between what is prescribed and what is used.

With that in mind, the optimal medication regimen should be simple, practical, affordable, effective, and well tolerated. Treatment that includes three different bottles of medication is unlikely to fulfill many of those criteria.

Dr. Fechtner recommended starting with a prostaglandin analogue and adding a second drug if further IOP-lowering is needed. However, he noted there are more than 56,000 possible combinations of topical glaucoma drugs and there have been few well-designed studies comparing the additivity of a second agent with a prostaglandin.

Beta-blockers are a popular choice, although other classes should not be overlooked, and in his practice, Dr. Fechtner indicated he often uses the fixed combination timolol/dorzolamide (Cosopt, Merck) for a second bottle.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.